Universität zu Köln

Hohberg, Melanie, Kobe, Carsten, Krapf, Philipp ORCID: 0000-0003-1671-2443, Taeger, Philipp, Hammes, Jochen, Dietlein, Felix, Zlatopolskiy, Boris D., Endepolst, Heike, Wild, Markus, Neubauer, Stephan, Heidenreich, Axel, Neumaier, Bernd, Drzezga, Alexander and Dietlein, Markus (2019). Biodistribution and radiation dosimetry of [F-18]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer. EJNMMI Res., 9. LONDON: SPRINGEROPEN. ISSN 2191-219X

Full text not available from this repository.

Abstract

AimWe investigated the whole-body distribution and the radiation dosimetry of [F-18]-JK-PSMA-7, a novel F-18-labeled PSMA-ligand for PET/CT imaging of prostate cancer.MethodsTen patients with prostate cancer and biochemical recurrence or radiologic evidence of metastatic diseases were examined with 329-384MBq (mean 359 17MBq) [F-18]-JK-PSMA-7. Eight sequential positron emission tomography (PET) scans were acquired from 20min to 3h after injection with IRB approval. The kidneys, liver, lungs, spleen, and salivary glands were segmented into volumes of interest using the QDOSE dosimetry software suite (ABX-CRO, Germany). Absorbed and effective dose were calculated using the ICRP-endorsed IDAC 1.0 package. The absorbed dose of the salivary glands was determined using the spherical model of OLINDA 1.1. PSMA-positive lesions were evaluated separately. Quantitative assessment of the uptake in suspicious lesions was performed by analysis of maximum (max) and peak SUV values. The gluteus maximus muscle (SUVmean) served as a reference region for the calculation of tumor-to-background ratios (TBR's).ResultsPhysiologic radiotracer accumulation was observed in the salivary and lacrimal glands, liver, spleen, and intestines, in a pattern resembling the distribution known from other PSMA-tracers with excretion via urinary and biliary pathways. The effective dose from [F-18]-JK-PSMA-7 for the whole body was calculated to be 1.09E-02mGy/MBq. The highest radiation dose was observed in the kidneys (1.76E-01mGy/MBq), followed by liver (7.61E-02mGy/MBq), salivary glands (4.68E-02mGy/MBq), spleen (1.89E-02mGy/MBq), and lungs (1.10E-2mGy/MBq). No adverse effects of tracer injection were observed. Six out of ten patients were scored as PSMA-positive. A total of 18 suspicious lesions were analyzed, which included six bone lesions, nine lymph nodes, and three local lesions within the prostate fossa. The values for the SUVmax and SUVpeak in the PSMA-positive lesions increased until 60min p.i. and remained at this intensity in the PET/CT scans until 140min. In the period between 170 and 200min after injection, a further significant increase in SUVmax and SUVpeak within the PSMA-positive lesions was observed.Conclusions The highest TBR of [F-18]-JK-PSMA-7 was found 3 h after injection. From the kinetically collected data, it can be concluded that this trend may also continue in the further course. The start of the PET/CT acquisition should be chosen as late as possible. The high uptake in suspicious lesions in terms of absolute SUVmax and relative TBR values indicates potentially high sensitivity of the tracer for detection of prostate cancer manifestations.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Hohberg, Melanie UNSPECIFIED UNSPECIFIED UNSPECIFIED Kobe, Carsten UNSPECIFIED UNSPECIFIED UNSPECIFIED Krapf, Philipp UNSPECIFIED orcid.org/0000-0003-1671-2443 UNSPECIFIED Taeger, Philipp UNSPECIFIED UNSPECIFIED UNSPECIFIED Hammes, Jochen UNSPECIFIED UNSPECIFIED UNSPECIFIED Dietlein, Felix UNSPECIFIED UNSPECIFIED UNSPECIFIED Zlatopolskiy, Boris D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Endepolst, Heike UNSPECIFIED UNSPECIFIED UNSPECIFIED Wild, Markus UNSPECIFIED UNSPECIFIED UNSPECIFIED Neubauer, Stephan UNSPECIFIED UNSPECIFIED UNSPECIFIED Heidenreich, Axel UNSPECIFIED UNSPECIFIED UNSPECIFIED Neumaier, Bernd UNSPECIFIED UNSPECIFIED UNSPECIFIED Drzezga, Alexander UNSPECIFIED UNSPECIFIED UNSPECIFIED Dietlein, Markus UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-134680
DOI:	10.1186/s13550-019-0540-7
Journal or Publication Title:	EJNMMI Res.
Volume:	9
Date:	2019
Publisher:	SPRINGEROPEN
Place of Publication:	LONDON
ISSN:	2191-219X
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PSMA; INHIBITOR; PROBE; ACID Multiple languages Radiology, Nuclear Medicine & Medical Imaging Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/13468